Discontinued — last reported Q4 '25
Business Segments · Exit and other-related costs
Oncology & Multispecialty — Exit and other-related costs
This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ4 2024
Last reportedQ4 2025May 8, 2026
Rolls up toBusiness Exit Costs
How to read this metric
Higher costs indicate significant operational changes or divestitures, which may signal a strategic pivot or consolidation of business activities.
Detailed definition
This metric captures the expenses incurred from exiting specific business activities, facilities, or product lines withi...
Peer comparison
Comparable to exit and disposal costs reported by peers undergoing portfolio optimization or segment-level restructuring.
Metric ID:
mck_segment_oncology_multispecialty_exit_and_other_related_costsHistorical Data
5 periods
| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $0 |
Range$0 – $0
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — exit and other-related costs?
- McKesson (MCK) reported oncology & multispecialty — exit and other-related costs of $0 in Q4 2025.
- What does oncology & multispecialty — exit and other-related costs mean?
- Costs associated with closing or exiting specific operations within the Oncology and Multispecialty segment.